Assess whether related-party sales should be backed out of valuation (7c0f66)

SITUATION After an earnout based on 'adjusted EBITDA' with no dictionary, QoE add-backs the seller marked 'normalized' is what customer-contract risk reviewer can touch in a family-office reviewing a manufacturing target. M&A Due Diligence will live with Proceed versus Reprice on this Legal, IP, and Regulatory file.

DECISION Customer-contract risk reviewer in a family-office reviewing a manufacturing target must choose Proceed / Reprice / Walk / Hold using QoE add-backs the seller marked 'normalized' after an earnout based on 'adjusted EBITDA' with no dictionary.

HYPOTHESES TO TEST 1. QoE add-backs the seller marked 'normalized' reads as Proceed once an earnout based on 'adjusted EBITDA' with no dictionary is lined up to the same M&A Due Diligence population. 2. QoE add-backs the seller marked 'normalized' is closer to Reprice after an earnout based on 'adjusted EBITDA' with no dictionary; Proceed would over-claim this Legal, IP, and Regulatory extract. 3. Walk is still live in QoE add-backs the seller marked 'normalized' for customer-contract risk reviewer in a family-office reviewing a manufacturing target. 4. QoE add-backs the seller marked 'normalized' is missing the fact customer-contract risk reviewer needs after an earnout based on 'adjusted EBITDA' with no dictionary; stop this M&A Due Diligence close.

ANALYSIS REQUIRED 1. Map reps, earnout mechanics, and integration risk a family-office reviewing a manufacturing target would inherit. 2. Tie quality-of-earnings, working-capital, and contingent items in QoE add-backs the seller marked 'normalized' to related-party sales should be. 3. Name the document customer-contract risk reviewer still needs before signing. 4. For this M&A Due Diligence Legal, IP, and Regulatory file, read QoE add-backs the seller marked 'normalized' against an earnout based on 'adjusted EBITDA' with no dictionary and write the one fact that would move related-party sales should be for customer-contract risk reviewer.

RECOMMENDATION Choose Proceed / Reprice / Walk / Hold on this M&A Due Diligence / Legal, IP, and Regulatory packet (QoE add-backs the seller marked 'normalized' after an earnout based on 'adjusted EBITDA' with no dictionary). Lead with the M&A Due Diligence option QoE add-backs the seller marked 'normalized' can support after an earnout based on 'adjusted EBITDA' with no dictionary, then the two facts that force it, then the Monday action for customer-contract risk reviewer in a family-office reviewing a manufacturing target.

COMMAND RETURNS - Bottom-line M&A Due Diligence option on related-party sales should be, then the evidence in QoE add-backs the seller marked 'normalized', then the action for customer-contract risk reviewer - Hypothesis scorecard against QoE add-backs the seller marked 'normalized': supported / rejected / untestable - Missing page in QoE add-backs the seller marked 'normalized' after an earnout based on 'adjusted EBITDA' with no dictionary, if any - Regulatory or exam hook Legal, IP, and Regulatory would cite